Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$5.33 - $8.18 $84,075 - $129,031
-15,774 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$5.5 - $9.19 $505,697 - $844,974
-91,945 Reduced 85.36%
15,774 $114,000
Q4 2021

Feb 10, 2022

BUY
$7.67 - $44.59 $826,204 - $4.8 Million
107,719 New
107,719 $963,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $275M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.